A double-blinded, prospective study to define antigenemia and quantitative real-time polymerase chain reaction cutoffs to start preemptive therapy in low-risk, seropositive, renal transplanted recipients

• Published in: Transplantation Vol. 98; no. 10; p. 1077
• Main Authors: David-Neto, Elias, Triboni, Ana H K, Paula, Flavio J, Vilas Boas, Lucy S, Machado, Clarisse M, Agena, Fabiana, Latif, Acram Z A, Alencar, Cecília S, Pierrotti, Ligia C, Nahas, William C, Caiaffa-Filho, Helio H, Pannuti, Claudio S
• Format: Journal Article
• Language: English
• Published: United States 27.11.2014
• Subjects: Adult; Antigens, Viral - blood; Antigens, Viral - genetics; Cytomegalovirus - genetics; Cytomegalovirus - immunology; Cytomegalovirus - isolation & purification; Cytomegalovirus Infections - diagnosis; Cytomegalovirus Infections - etiology; Cytomegalovirus Infections - virology; Double-Blind Method; Early Diagnosis; Female; Humans; Kidney Transplantation - adverse effects; Male; Middle Aged; Phosphoproteins - blood; Phosphoproteins - genetics; Phosphoproteins - immunology; Predictive Value of Tests; Prospective Studies; Real-Time Polymerase Chain Reaction; Risk Factors; Viral Matrix Proteins - blood; Viral Matrix Proteins - genetics; Viral Matrix Proteins - immunology; Viremia - diagnosis; Viremia - etiology; Viremia - virology

Cytomegalovirus (CMV) disease occurs in 16% to 20% of low-risk, CMV-positive renal transplant recipients. The cutoffs for quantitative real-time polymerase chain reaction (qPCR) or phosphoprotein (pp65) antigenemia (pp65emia) for starting preemptive therapy have not been well established. We measure...